Castle Biosciences (CSTL) Q1 2025 Earnings
Castle Biosciences reported Q1 2025 revenue of $88.0M (+20.6% YoY), beat analyst consensus of $71.8M by $16.2M. Diluted EPS came in at $-0.20 (-122.2% YoY), missed the $-0.08 consensus by $0.12.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Castle Biosciences's Q1 2025 earnings report.
Castle Biosciences (CSTL) reported Q1 2025 earnings on May 5, 2025 after market close.
Castle Biosciences reported revenue of $88.0M and diluted EPS of $-0.20 for Q1 2025.
Revenue beat the consensus estimate of $71.8M by $16.2M. EPS missed the consensus estimate of $-0.08 by $0.12.
Compared to the same quarter a year prior, revenue grew 20.6% from $73.0M a year earlier and diluted EPS declined 122.2% from $-0.09.
You can read the 10-Q periodic report (0001447362-25-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.